Home Analyst Ratings Wells Fargo lowers Amphastar Pharmaceuticals rating to Equal-Weight and sets price...

Wells Fargo lowers Amphastar Pharmaceuticals [AMPH] rating to Equal-Weight and sets price target at $21

Wells Fargo took its Amphastar Pharmaceuticals [AMPH] rating to the equivalent of Equal-Weight from Overweight, and the price target to $21.0, in a research note dated 2021-01-08. That figure represents around a 1.69% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Northland Capital’s analysts upgrading the shares from “a Market perform” rating to “an Outperform” rating in a research note to investors issued in early October. Meanwhile, Northland Capital had launched its coverage on AMPH with “an Outperform”, in a research note produced for clients May 01, 2020. In addition, there was a downgrade from Piper Jaffray on March 13, 2019. The rater changed AMPH from “an Overweight” to “a Neutral”.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is Amphastar Pharmaceuticals Inc. [NASDAQ:AMPH] a Good Buy Right Now?

It should be noted that AMPH technical indicators for short, intermediate as well as long term progress have placed an overall average of 40% as Buy. The average signal changed from 8% Buy in the last week and compares with 72% Sell in the past month. Data from Amphastar Pharmaceuticals Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 0.23 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.21 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.2 million shares.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


AMPH Price Performance

On Wall Street, Amphastar Pharmaceuticals Inc. [NASDAQ:AMPH] finished Thursday’s session up 2.74% at $20.65. The stock went up to $20.93 at the same session while its lowest single day price was $19.73. In the last five days, it saw a rise of about 4.03%, Amphastar Pharmaceuticals Inc. shares gained by almost 2.69% since the beginning of the year. However, the share price has dropped to as low as -8.99% below its one year high. On 01/07/21, the company shares recorded $20.93, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/05/21, the same year at $19.67. The company’s shares have inclined by 10.96% in the past year. The 50-day SMA achieved is $19.13 while the 200-day SMA is $19.20. Volume dropped to 0.19 million from 0.38 million in the previous session.

Amphastar Pharmaceuticals Inc. [AMPH] Valuation Measures

Notably, Amphastar Pharmaceuticals Inc. [AMPH] stock cannot be classified as a good candidate in the listing of underestimated low-priced Drug Manufacturers – Specialty & Generic companies to purchase soonest possible with the prevailing 12-month PE ratio of 154.10. The measure means the stock is exchanging at a premium as compared to the 24.75x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 2.87 PS value ratio is reported for the last one year of reported earnings. That is lower than the industry average of 2.92 which means AMPH serve an unattractive investment opportunity compared to its competitors.

AMPH Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 19.94 level, and in case of violation of this particular level, it will cause more drop to 19.24 level. On the upper level, 21.64 is still the key resistance. The stock may increase to the subsequent resistance at 21.14. The Relative Strength Index (RSI) pinned on the 14-day chart is 68.69, implying a neutral technical stance while the MACD stands at 0.79, meaning price will decrease in the next trading period. Percent R indicator moved to 10.14%, implying bullish price movement. Stochastic %K at 80.06% suggest selling the stock.

What is the short interest in Amphastar Pharmaceuticals Inc.?

Short interest in the Amphastar Pharmaceuticals Inc. stock has surged, increasing by 0.11 million shares to total 2.58 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 2.69 million, data from Yahoo Finance shows. The decrease of -4.26% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 8.51% of the overall float for the stock.

Amphastar Pharmaceuticals Inc.’s Biggest Shareholders: Who Owns Amphastar Pharmaceuticals Inc. [AMPH]?

Filings by BlackRock Fund Advisors showed that the firm now holds a total of 6,013,516 shares or roughly 12.66% of the outstanding AMPH shares. This means their shares have increased by 217,790 from the 6,013,516 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Federated Global Investment Manag updated stake is worth $46,220,986. Details in the latest 13F filings reveal that The Vanguard Group, Inc. acquired their 1.00% stake valued at $40,886,735 while Dimensional Fund Advisors LP cut theirs at $32,429,636. During the last quarter, The Vanguard Group, Inc. raised 22,828 of its shares in Amphastar Pharmaceuticals Inc. while Dimensional Fund Advisors LP sold -16,829 shares. The Invesco Capital Management LLC’s holdings currently number 1,350,417 shares at $27886111.05. According to the firm’s last 13F report, SSgA Funds Management, Inc. shares in the company at filing stood at 1,290,490 shares, roughly $22,919,102.

AMPH Earnings Forecast For The Current Quarter

Amphastar Pharmaceuticals Inc. [AMPH] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $89.01M and an earnings per share of $0.14 for Dec 2020. Looking further ahead, the company is expected to report revenue of $93.25M at an EPS of $0.17 for Mar 2021. The estimates represent upside of 26.50% and 88.89% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

AMPH Earnings Estimates For The Current Year

For the financial year, Amphastar Pharmaceuticals Inc. [NASDAQ:AMPH] is expected to bring in revenue of $342.5M. The returns are nearly $20.14 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 0.6, higher than that of FY19 by $0.24. Estimates put this year’s earnings growth at 66.70%, 90.00% for the next, and at an annual 25.00% over the next 5-year period. As for sales, forecasts are for an increase of 6.20% in the current fiscal year and a further 26.50% over the following year.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Inpixon (INPX) Building its Reputation in the market

INPX Getting Boost:  Inpixon recently got a huge amount of recognition from various firms. INPX company was commended by Gartner and by IoT Sensor company....

Top Recent Developments that lead to the ConforMIS Inc (CFMS) stock back on its track:

How CFMS performed: During a pandemic, different companies suffered from major losses. According to a study, there was a 53% reduction in adult heart surgeries....

The Reason Behind More Than 100% Pre-Market Rise Of NanoViricides, Inc. (NNVC) Stock

The stock of drug-maker NanoViricides, Inc. (NNVC) has been skyrocketing in the pre-market trades today. As of 08:24 a.m. EST, the stock was priced...

What Drove The STRATA Skin Sciences, Inc. (NASDAQ: SSKN) Stock In Extended Trading?

Shares of dermatology-focused company STRATA Skin Sciences, Inc. (NASDAQ: SSKN) leapt 15.03% to $1.99 in the trading after ring of the bell on Monday....

Why Sundial Growers (SNDL) shares have skyrocketed in intraday trading?

Shares of Sundial Growers (SNDL) have been on a skywalk. As of 10:47 AM EST, the seller, and producer of Cannabis products recorded $1.38...

Top Recent Developments that lead to the ConforMIS Inc (CFMS) stock back on its track:

How CFMS performed: During a pandemic, different companies suffered from major losses. According to a study, there was a 53% reduction in adult heart surgeries....

CHF Solutions, Inc. (CHFS): Why Is It Upticking Today?

The medical device company CHF Solutions, Inc. (Nasdaq: CHFS) started today’s trading on a positive note. As of 10:51 a.m. EST, the stock was...

Is It Because The Stock of Communications Systems, Inc. (JCS) Is Climbing 111% Pre-Market?

In pre-market session today, Communications Systems, Inc. (JCS) shares have been rising aggressively. As of 09:16 a.m. EST, the stock was at a rise...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.